Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

midostaurin

- PMLiVE

Novartis’ Cosentyx scores again in phase 3, strengthens approval claim

Scopes approval in non-radiographic axial spondyloarthritis

- PMLiVE

NICE turns down Roche’s Tecentriq for triple-negative breast cancer

Will also not be included in the Cancer Drugs Fund

- PMLiVE

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

Hopes to boost haematology franchise with lead drug Doptelet

- PMLiVE

NICE delivers final ‘no’ for Novartis’ migraine treatment Aimovig

Blow to patients who have dubbed the treatment 'life-saving'

Novartis building

Novartis points finger at AveXis execs in Zolgensma data scandal

Announces remediation plan including whistleblower scheme

- PMLiVE

Takeda’s HAE drug Takhzyro backed by NICE

New treatment option for rare, hereditary disease

- PMLiVE

Distribution of Novartis’ generic Zantac halted due to carcinogen concerns

Ranitidine medicines found to contain cancer-causing substance

- PMLiVE

Novartis eyes potential new indication for Cosentyx

Unveils positive late-stage results in axial spondyloarthritis

Biomarin

NICE approves BioMarin’s Brineura after initial setback

First treatment for rare disease

- PMLiVE

Novartis’ CAR-T Kymriah scores SMC approval

Will now be available on NHS across the UK

- PMLiVE

Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation

Provides hope for new treatment of rare cancer

- PMLiVE

NICE backs NHS use of Novartis’ gene therapy Luxturna

First and only therapy for rare, inherited form of blindness

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links